Supplementary Information
ICH, FIP
FIP
The first-in-patient (FIP) starting dose for oncology agents should be reasonably safe and provide potential therapeutic benefit to the patient. For late-stage oncology patients, this dose is often based on the ICH S9 guidance, which was developed primarily based on experience with cytotoxic chemotherapeutic agents using the rodent STDThe online version contains supplementary material available at 10.1007/s00280-023-04570-3.